GR Madhavan’s research while affiliated with National Institute of Technology Andhra Pradesh and other places

What is this page?


This page lists works of an author who doesn't have a ResearchGate profile or hasn't added the works to their profile yet. It is automatically generated from public (personal) data to further our legitimate goal of comprehensive and accurate scientific recordkeeping. If you are this author and want this page removed, please let us know.

Publications (7)


ChemInform Abstract: Novel Indole Containing Thiazolidinedione Derivatives as Potent Euglycemic and Hypolipidaemic Agents
  • Article

August 2010

·

27 Reads

ChemInform

B. B. LOHRAY

·

V. BHUSHAN

·

P. B. RAO

·

[...]

·

R. RAJAGOPALAN

ChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 100 leading journals. To access a ChemInform Abstract of an article which was published elsewhere, please select a “Full Text” option. The original article is trackable via the “References” option.





Novel phthalazinone and benzoxazinone containing thiazolidinediones as antidiabetic and hypolipidemic agents

August 2001

·

53 Reads

·

97 Citations

European Journal of Medicinal Chemistry

We report here the synthesis of a series of 5-[4-[2-[substituted phthalazinones-2(or 4)yl]ethoxy]phenylmethyl]thiazolidine-2,4-diones and 5-[4-[2-[2,3-benzoxazine-4-one-2-yl]ethoxy]phenylmethyl]thiazolidine-2,4-diones and their plasma glucose and plasma triglyceride lowering activity in db/db mice. In vitro PPARgamma transactivation assay was performed in HEK 293T cells. In vitro and in vivo pharmacological studies showed that the phthalazinone analogue has better activity. PHT46 (compound 5a), the best compound in this series, showed better in vitro PPARgamma transactivation potential than troglitazone and pioglitazone. In insulin resistant db/db mice, PHT46 showed better plasma glucose and triglyceride lowering activity than the standard drugs. Pharmacokinetic study in Wistar rats showed good systemic exposure of PHT46. Subchronic toxicity study in Wistar rats did not show any treatment-related adverse effect.


Novel Euglycemic and Hypolipidemic Agents. 1 †

May 1998

·

30 Reads

·

111 Citations

Journal of Medicinal Chemistry

A series of [[(heterocyclyl)ethoxy]benzyl]-2,4-thiazolidinediones have been synthesized by the condensation of corresponding aldehyde 1 and 2,4-thiazolidinedione followed by hydrogenation. Both unsaturated thiazolidinedione 2 and its saturated counterpart 3 have shown antihyperglycemic activity. Many of these compounds have shown superior euglycemic and hypolipidemic activity compared to troglitazone (CS 045). The indole analogue DRF-2189 (3g) was found to be a very potent insulin sensitizer, comparable to BRL-49653 in genetically obese C57BL/6J-ob/ob and 57BL/KsJ-db/db mice. Pharmacokinetic and tissue distribution studies conducted on BRL-49653 and DRF-2189 (3g) indicate that these drugs are well-distributed in target tissues. On the basis of euglycemic activity as well as enhanced selectivity against reduction of triglycerides in plasma, DRF-2189 (3g) has been selected for further evaluation.


Citations (4)


... With the aim to develop a more efficient synthetic process for the synthesis of highly functionalized 5-arylidene rhodanines 3a-v from the building blocks 1a-i and 2a-p, microwave irradiation was employed to shorten the reaction times in comparison to conventional heating. For the reported methods, the Knoevenagel condensations have been realized in the presence of catalyst with various solvents: sodium acetate in glacial acetic acid [48] or in ethanol [46], piperidinium benzoate in toluene [49], tetrabutylammonium bromide in water [50], and piperidine in ethanol [51], using conventional heating in an oil bath. These older protocols suffer from one or more limitations, such as requiring harsh reaction conditions, low moderate yields, cumbersome experimental process, and long reaction time. ...

Reference:

Design and Microwave Synthesis of New (5Z) 5-Arylidene-2-thioxo-1,3-thiazolinidin-4-one and (5Z) 2-Amino-5-arylidene-1,3-thiazol-4(5H)-one as New Inhibitors of Protein Kinase DYRK1A
Novel Indole Containing Thiazolidinedione Derivatives as Potent Euglycemic and Hypolipidaemic Agents
  • Citing Article
  • December 1997

Bioorganic & Medicinal Chemistry Letters

... The helix-turn-helix (HTH) motif is instrumental to many DNA-binding proteins such as transcription factors that are capable of recognizing a particular DNA sequence for regulatory purposes [27]. To develop chemical probes gauging DNA-protein interactions, Iqbal et al. designed cyclic peptides bridged by a meta benzene ring such as 10 ( Figure 2A) [28]. As the final step of their synthesis, acyclic substrate 9 was treated with Pd(OAc) 2 , tri(o-tolyl)phosphine, and diisopropylethylamine in refluxing acetonitrile for 36 h. ...

Synthesis of Small Cyclic Peptides via Intramolecular Heck Reactions
  • Citing Article
  • April 2003

Tetrahedron Letters

... The substituents at carbon-2 and carbon-3 of indole significantly reduce the euglycemic and hypolipidemic actions. [16,17] Darwish KM developed, produced, and tested a unique class of thiazolidinediones (TZDs) from benzhydrol and indole for their binding affinity to two receptors: PPAR-E and FFAR1, also known as GPCR40. There are three compounds that have a high affinity for both targets. ...

Novel Euglycemic and Hypolipidemic Agents. 1 †
  • Citing Article
  • May 1998

Journal of Medicinal Chemistry

... The phthalazin-1(2H)-one scaffold is one valuable diazaheterocyclic scaffold due to its wide pharmacological profile [1] as well as its applications in agrochemicals [2] and functional materials. [3] In particular, the phthalazin-1(2H)-ones bearing substitutions on C4-position display potent medicinal properties as anticancer, [4] antimicrobial, [5] anti-inflammatory, [6] antihypertensive, [7] antidiabetic [8] and neuroprotective [9] agents ( Figure 1). ...

Novel phthalazinone and benzoxazinone containing thiazolidinediones as antidiabetic and hypolipidemic agents
  • Citing Article
  • August 2001

European Journal of Medicinal Chemistry